MedTrace Logo

Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients

NCT04642378 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2024-04-16

No results posted yet for this study

Summary

This is a multi-center, single-blind, parallel group, randomized controlled trial to access the effect and safety of the Artificial Intelligence Assisted Insulin Titration System (iNCDSS) in patients with Type 2 Diabetes Mellitus.

Conditions

Interventions

DRUG

iNCDSS based insulin regime

Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).

DRUG

routine insulin treatment regime

Patients of this group will receive the insulin regime recommended by professional endocrinologists.

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • XuHui Central Hospital of Shanghai, Shanghai, China

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Xiaoying Li, MD · Shanghai Zhongshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-09-08
Completion
2022-09-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04642378 on ClinicalTrials.gov